Physician profile
James E Fagelson
NPI 1558354928
$3,470.31
in general payments reported to CMS, 2019-2025
21 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $1,414 · 2021: $327 · 2022: $681 · 2023: $58.37 · 2024: $292 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,615.97 | 2019-2025 | Lithovue, Rezum Generator |
| Procept Biorobotics Corporation | $440.20 | 2022 | |
| Dendreon Pharmaceuticals LLC | $394.31 | 2020-2024 | Provenge |
| Astellas Pharma US INC | $204.83 | 2021-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $181.08 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $87.34 | 2023-2025 | Orgovyx, Gemtesa |
| Olympus America INC. | $75.58 | 2022-2025 | Itind System |
| Abbvie INC. | $68.30 | 2019-2024 | |
| Myovant Sciences INC. | $49.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.21 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Accord Healthcare, INC. | $37.83 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $34.87 | 2020-2023 | |
| Progenics Pharmaceuticals, INC. | $34.58 | 2022 | |
| Teleflex LLC | $34.13 | 2021-2022 | |
| 180 Medical, INC. | $32.56 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $28.64 | 2021 | |
| Allergan, INC. | $26.95 | 2021-2022 | |
| Pfizer INC. | $23.85 | 2025 | |
| Janssen Biotech, INC. | $20.04 | 2021 | |
| Dornier Medtech America, INC | $18.60 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fagelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.